Key result
Administration of a P2Y12 receptor antagonist for 12 weeks significantly reduced atheroma and decreased the abundance of vascular smooth muscle cells in plaques in apolipoprotein E-deficient mice.
Why the study?
Does P2Y12 receptor antagonism reduce atheroma progression and VSMC migration in atherosclerosis models?
Does P2Y12 receptor antagonism reduce atheroma progression and VSMC migration in atherosclerosis models?
Vessel wall P2Y12 receptor promotes VSMC migration through cofilin dephosphorylation, and its antagonism reduces atheroma progression, suggesting a therapeutic target for atherosclerosis.
No takes yet. Share an insight, caveat, or question.
P2Y12 antagonism may limit plaque progression; hypothesis-generating in animals and leaves open human translation.
Niu et al. (2017) studied Atherosclerosis. P2Y12 receptor antagonist was evaluated on Atheroma reduction and VSMC abundance in plaque. Administration of a P2Y12 receptor antagonist for 12 weeks significantly reduced atheroma and decreased the abundance of vascular smooth muscle cells in plaques in apolipoprotein E-deficient mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: